Software tasked with designing a type-II kinase inhibitor suggests 97 candidates in 10 minutes, three of which were both ...
The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback